From: Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy
Name | Target | Clinical trial no | Phase | Disease | H3S10ph source |
---|---|---|---|---|---|
Barasertib (AZD1152-HQPA|AZD281) | AURKB/A | NCT03366675; NCT03217838 | Phase 1/2 | Small cell lung cancer, acute myeloid leukemia /high-risk myelodysplastic syndrome, advanced solid tumors | [149] |
Flavopiridol | CDKs, including CDK8 | NCT03593915; NCT03441555; NCT03563560 | Phase 1/2 | Myelodysplastic syndromes; acute myeloid leukemia | |
BI-847325 | AURKA/B/C | NCT01324830 | Phase 1 | Solid tumors | [152] |
Alisertib | AURKA | NCT02860000 | Phase 2 | Breast cancer | [91] |
SEL120 | CDK8 | NCT04021368 | Phase 1 | Acute myeloid leukemia or high-risk myelodysplastic syndrome | [153] and unpublished observations |
SEL24/MEN1703 | PIM kinases | NCT03008187 | Phase 1/2 | Acute myeloid leukemia | [154] |
PIM447 | PIM kinases | NCT02370706 | Phase 1 | Myelofibrosis |